Citace podle APA

Fishman, M. (2019). Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer (“KEYNOTE 045”). Transl Androl Urol.

Styl Chicago

Fishman, Mayer. "Commentary: 2-year Follow Up of Pembrolizumab As Second-line Therapy for Advanced Urothelial Cancer (“KEYNOTE 045”)." Transl Androl Urol 2019.

Citace podle MLA

Fishman, Mayer. "Commentary: 2-year Follow Up of Pembrolizumab As Second-line Therapy for Advanced Urothelial Cancer (“KEYNOTE 045”)." Transl Androl Urol 2019.

Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..